Targeting of a Head and Neck Squamous Cell Carcinoma Xenograft Model Using the Chimeric Monoclonal Antibody U36 Radioiodinated with a closo-Dodecaborate-containing Linker

References

• Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124: 951–62.
   PubMedGoogle Scholar
• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43.
   PubMed Web of Science ®Google Scholar
• Alvi A, Johnson JT. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 1997; 19: 500–5.
   PubMed Web of Science ®Google Scholar
• Gerretsen M, Quak JJ, Brakenhoff RH, Snow GB, van Dongen GA. The feasibility of radioimmunotherapy of head and neck cancer. Eur J Cancer B Oral Oncol 1994; 30: 82–7.
   Google Scholar
• Quak J, van Dongen G. Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors. Eur Arch Otorhinolaryngol 1994; 251: 1–5.
   PubMedGoogle Scholar
• Schrijvers AM, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993; 53: 4383–90.
   Google Scholar
• Van Hal NL, Van Dongen GA, Ten Brink CB, Herron JN, Snow GB, Brakenhoff RH. Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. Cancer Immunol Immunother 1997; 45: 88–92.
   PubMedGoogle Scholar
• de Bree R, Kuik DJ, Quak JJ, Roos JC, van den Brekel MW, Castelijns JA, et al. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur J Nud Med 1998; 25: 1562–5.
   Google Scholar
• Colnot DR, Nieuwenhuis EJ, van den Brekel MW, Pijpers R, Brakenhoff RH, Snow GB, et al. Head and neck squamous cell carcinoma: US-guided fine-needle aspiration of sentinel lymph nodes for improved staging-initial experience. Radiology 2001; 218: 289–93.
   Google Scholar
• Wheldon TE, O'Donoghue JA. The radiobiology of targeted radiotherapy. Int J Radiat Biol 1990; 58: 1–21.
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Orlova A, Lundqvist H. Approaches to improvement of cellular retention of radiohalogen labels delivered by internalizing tumor targeting proteins and peptides. Curr Med Chem 2003; 10: 1241–53.
   Google Scholar
• Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56: 2123–9.
   Google Scholar
• Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 1997; 57: 1510–5.
   Google Scholar
• Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radio-iodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an inter-nalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 2000; 60: 4453–60.
   PubMed Web of Science ®Google Scholar
• Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nud Med 1998; 25: 201–12.
   Google Scholar
• Sivaev IB, Bruskin AB, Nesterov VV, Antipin MYu, Bregadze VI, Sjoeberg S. Synthesis of Schiff bases derived from the ammoniaundecahydro-closo-dodeca-borate(1-) anion, [B12H11NH:CHR]-, and their reduc-tion into monosubstituted amines [B12H11NH2CH2R]-: a new route to water soluble agents for BNCT. Inorg Chem 1999; 38: 5887–93.
   Google Scholar
• Tolmachev V, Orlova A, Bruskin A, Sivaev I, Persson M, Sjoberg S, et al. The use of benzyl isothiocyanate derivative of closo-dodecaborate dianion for indirect radioiodination and radiobromination of monoclonal antibodies. Eur J Nud Med 2002; 29\(Suppl. 1): 76.
   Google Scholar
• Nestor M, Persson M, Cheng J, Tolmachev V, van Dongen G, Anniko M, et al. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 2003; 14: 805–10.
   PubMedGoogle Scholar
• Koziorowski J, Henssen C, Weinreich R. A new con-venient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for iodination of proteins. Appl Radiat Isot 1998; 49: 955–9.
   Google Scholar
• Watanabe Y, Endo K, Koizumi M, Kawamura Y, Saga T, Sakahara H, et al. Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice. Cancer Res 1989; 49: 2884–9.
   PubMedGoogle Scholar
• Michel RB, Ochakovskaya R, Mattes MJ. Antibody localization to B-cell lymphoma xenografts in immuno-deficient mice: importance of using residualizing radi-olabels. Clin Cancer Res 2002; 8: 2632–9.
   Google Scholar
• Henderson LA, Baynes JW, Thorpe SR. Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 1982; 215: 1–11.
   PubMedGoogle Scholar
• Zalutsky MR, Narula AS. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate intermediate. Cancer Res 1988; 48: 1446–50.
   PubMedGoogle Scholar
• Wilbur DS, Hadley SW, Grant LM, Hylarides MD. Radioiodinated iodobenzoyl conjugates of a monoclo-nal antibody Fab fragment. In vivo comparisons with chloramine-T-labeled Fab. Bioconjug Chem 1991; 2: 111–6.
   Google Scholar
• Tolmachev VKJ, Sivaev I, Lundqvist H, Carlsson J, Orlova A, Gedda L, et al. Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. Bioconjug Chem 1999; 10: 338–45.
   PubMedGoogle Scholar